Loading clinical trials...
Loading clinical trials...
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the can...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Merck Sharp & Dohme LLC
NCT02600949 · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, and more
NCT07446322 · Ras-mutated Metastatic Colorectal Cancer, mCRC, and more
NCT05919264 · Cancer, Colorectal Cancer, and more
NCT06921928 · Gastric Cancer, Gastroesophageal Junction Cancer, and more
NCT06423326 · Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, and more
UCLA ( Site 0317)
Los Angeles, California
University of Colorado Anschutz Medical Campus ( Site 0299)
Aurora, Colorado
University of Colorado Anschutz Medical Campus ( Site 0325)
Aurora, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions